Upside case
Bull case
$218+71.7%
A would need investors to value it at roughly 36x earnings — about 15x more generous than today's 21x forward P/E. That requires meaningful multiple expansion on top of continued earnings growth.
Analysis OverviewBuyUpdated Jun 18, 2026
Agilent Technologies, Inc. (A) Stock Analysis
Wall Street verdict, consensus price target, and analyst rating breakdown — everything needed to frame the risk/reward at today's price.
Analyst consensus
Buy
Covering
41
analysts
32 bullish · 1 bearish · 41 covering A
Strong Buy
1
Buy
31
Hold
8
Sell
1
Strong Sell
0
Consensus Target
$155
+21.8% vs today
Scenario Range
$104 – $218
Model bear to bull value window
Coverage
41
Published analyst ratings
Valuation Context
21.0x
Forward P/E · Market cap $35.9B
A price targets
Three scenarios for where A stock could go
Current
~$127
Confidence
51 / 100
Updated
Jun 18, 2026
Where we are now
Current · $127
Bear
$104
Base
$166
Bull
$218
Market caseClosest to today
Base case
$166+30.3%
At 27x on FY1 earnings, the base case reflects a reasonable but not stretched valuation. It prices in continued growth without assuming an exceptional setup.
Stress case
Bear case
$104-17.9%
If investor confidence fades or macro conditions deteriorate, a 4x multiple contraction could push A down roughly 18% from where it trades now.
Not financial advice. Model confidence reflects internal scenario assumptions, not a guarantee of returns. Past performance does not predict future results.
Agilent Technologies, Inc.
A · NYSEHealthcareMedical - Diagnostics & ResearchOctober year-end
Agilent Technologies is a life sciences and diagnostics company that provides analytical instruments, software, and services to laboratories worldwide. It generates revenue primarily from selling laboratory instruments and consumables (~70% of sales) and related services (~30%), with its Life Sciences & Applied Markets segment contributing about 60% of revenue and Diagnostics & Genomics around 40%. The company's competitive advantage lies in its deep application expertise across multiple scientific domains—particularly in chromatography and mass spectrometry—and its sticky customer relationships built on complex, integrated workflow solutions.
Market Cap
$35.9B
Revenue TTM
$7.2B
Net Income TTM
$1.4B
Net Margin
19.6%
A Revenue and Earnings Performance
Quarterly beat-or-miss track record against analyst estimates, plus forward revenue and EPS outlook for the next two fiscal years.
EPS Beat Rate
83%Exceptional
12 quarters tracked
Revenue Beat Rate
75%Exceptional
vs consensus estimates
Avg EPS Surprise
+3.0%
above Street consensus
Beat / Miss Record
BeatMissLeft = EPS · Right = Revenue
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Last 4 Quarters
EPS beats: 3 of 4Q3 2025
EPS
$1.37/$1.37
Revenue
$1.7B/$1.7B
Q4 2025
EPS
$1.59/$1.58
Revenue
$1.8B/$1.8B
Q1 2026
EPS
$1.36/$1.37
Revenue
$1.8B/$1.8B
Q2 2026
EPS
$1.49/$1.41
Revenue
$1.8B/$1.8B
| Quarter | EPS (Actual / Est) | EPS Surprise | Revenue (Actual / Est) | Rev Surprise |
|---|---|---|---|---|
| Q3 2025 | $1.37/$1.37 | +0.0% | $1.7B/$1.7B | +3.2% |
| Q4 2025 | $1.59/$1.58 | +0.4% | $1.8B/$1.8B | +0.4% |
| Q1 2026 | $1.36/$1.37 | -0.7% | $1.8B/$1.8B | -0.5% |
| Q2 2026 | $1.49/$1.41 | +5.7% | $1.8B/$1.8B | +2.0% |
FY1–FY2 Estimates
Revenue Outlook
FY1
$7.4B
+2.7% YoY
FY2
$7.8B
+4.4% YoY
EPS Outlook
FY1
$5.45
+9.5% YoY
FY2
$5.83
+6.9% YoY
Trailing FCF (TTM)$1.3B
FCF Margin: 17.4%
Next Earnings
—
Expected EPS
—
Expected Revenue
—
A beat EPS estimates in 3 of 4 tracked quarters. A strong delivery record supports forward estimate credibility.
A Revenue Breakdown by Segment
Product and geographic revenue mix from the latest annual disclosure, with year-over-year growth by segment.
Latest disclosure
FY 2025
Total disclosed revenue $6.9B
Product Mix
Latest annual revenue by segment or product family
Agilent CrossLab
41.9%
+76.9% YoY
Tap, hover, or focus a slice to inspect segment detail.
Geographic Mix
Latest annual revenue by reported region
Americas
40.4%
+9.1% YoY
Tap, hover, or focus a slice to inspect segment detail.
Agilent CrossLab is the largest disclosed segment at 41.9% of FY 2025 revenue, up 76.9% YoY.
Americas is the largest reported region at 40.4%, up 9.1% YoY.
A Valuation Snapshot
Current multiples compared to the S&P 500, the company's sector, and its own five-year average.
Relative Value Signal
Slightly cheap versus peers
Fair value est. $144 — implies +13.7% from today's price.
Upside to Fair Value
13.7%
potential upside
Deep DiscountFair ValueVery Expensive
vs S&P 500 Trailing P/E
A
27.8x
vs
S&P 500
24.4x
+14% premium
vs Healthcare Trailing P/E
A
27.8x
vs
Healthcare
22.1x
+26% premium
vs A 5Y Avg P/E
Today
27.8x
vs
5Y Average
31.8x
13% discount
Forward PE
21.0x
S&P 500
18.8x
+11%
Healthcare
18.3x
+15%
5Y Avg
—
—
Trailing PE
27.8x
S&P 500
24.4x
+14%
Healthcare
22.1x
+26%
5Y Avg
31.8x
-13%
PEG Ratio
1.89x
S&P 500
1.66x
+14%
Healthcare
1.59x
+19%
5Y Avg
—
—
EV/EBITDA
21.2x
S&P 500
15.2x
+39%
Healthcare
14.2x
+49%
5Y Avg
23.8x
-11%
Price/FCF
31.2x
S&P 500
20.7x
+51%
Healthcare
18.5x
+68%
5Y Avg
32.5x
-4%
Price/Sales
5.2x
S&P 500
3.1x
+67%
Healthcare
2.6x
+96%
5Y Avg
6.0x
-14%
Dividend Yield
0.78%
S&P 500
1.91%
-59%
Healthcare
1.50%
-48%
5Y Avg
0.67%
+16%
| Metric | A | S&P 500 | Healthcare | 5Y Avg A |
|---|---|---|---|---|
| Forward PE | 21.0x | 18.8x+11% | 18.3x+15% | — |
| Trailing PE | 27.8x | 24.4x+14% | 22.1x+26% | 31.8x-13% |
| PEG Ratio | 1.89x | 1.66x+14% | 1.59x+19% | — |
| EV/EBITDA | 21.2x | 15.2x+39% | 14.2x+49% | 23.8x-11% |
| Price/FCF | 31.2x | 20.7x+51% | 18.5x+68% | 32.5x |
| Price/Sales | 5.2x | 3.1x+67% | 2.6x+96% | 6.0x-14% |
| Dividend Yield | 0.78% | 1.91% | 1.50% | 0.67% |
A trades above S&P 500 benchmarks on 6 of 6 measured multiples — commands a broad premium across most valuation dimensions.
Forward P/E and PEG reflect analyst consensus estimates. Historical averages use trailing ratios where forward data is unavailable.S&P 500 and sector benchmarks both use trailing median P/E — similar readings indicate the broader index and sector are priced alike.
Open valuation toolA Financial Health
Verdict
Strong
A generates $1.3B in free cash flow at a 17.4% margin — 13.5% ROIC signals a durable competitive advantage · returns 2.0% of market cap to shareholders annually.
Cash Engine
Revenue, margins, and cash generation
Revenue (TTM)
Trailing-twelve-month sales base
$7.2B
Revenue Growth
TTM vs prior year
+9.1%
Gross Margin
Gross profit as a share of revenue
53.0%
Operating Margin
Operating income divided by revenue
21.5%
Net Margin
Net income divided by revenue
19.6%
EPS (TTM)
Diluted earnings per share, trailing twelve months
$4.98
Free Cash Flow (TTM)
Cash generation after capex
$1.3B
FCF Margin
FCF as share of revenue — the primary cash quality signal
17.4%
Capital Quality
ROIC, leverage, and debt serviceability
ROIC
Return on invested capital — primary competitive quality signal
13.5%
ROA
Return on assets, trailing twelve months
11.1%
Cash & Equivalents
Liquid assets on the balance sheet
$1.8B
Net Debt
Total debt minus cash
$1.6B
Debt Serviceability
Net debt as a multiple of annual free cash flow
1.2× FCF
~1.2 years to full repayment at current FCF run-rate
ROE
Return on equity, trailing twelve months
20.8%
Shareholder Returns
How capital is returned to owners
Total shareholder yield
2.0%
Dividend
0.8%
Buyback
1.2%
Share Repurchases
Trailing buyback outflow — dollar magnitude of capital returned
$425M
Dividend / Share
Annualized trailing dividend per share
$0.99
Payout Ratio
Share of earnings distributed as dividends
21.6%
Shares Outstanding
Declining as buybacks retire shares
282M
All figures from the trailing twelve months. ROIC uses invested capital (equity + net debt).
Open full ratios pageA Stock Risk Factors
Key factors that could pressure the stock price, compress the multiple, or weigh on future results.
AI analysis · updated June 18, 2026
Medium
Global tariffs impact
Persisting pressures from global tariffs are affecting Agilent's performance despite stable fundamentals.
Medium
Supply chain issues
Supply chain disruptions are contributing to downward pressure on Agilent's stock despite positive long-term outlook.
Lower
Market sentiment
Weak sentiment and profit-taking have led to stock price declines, even with stable quarterly results.
High Risk
Revenue guidance risks
While Agilent raised full-year 2026 revenue guidance, market concerns persist about achieving these targets amid external pressures.
These are risk mechanisms, not predictions. The key question is which would force a cut to earnings estimates or a lower multiple than the market currently prices in.
Why A Stock Could Outperform
Structural drivers behind the upside case and why the stock could outperform over the next 12 months.
AI analysis · updated June 18, 2026
Scientific Solutions Leadership
Agilent provides comprehensive scientific solutions that help customers achieve superior outcomes in labs, clinics, and businesses, reinforcing its market leadership.
Bullish Investment Thesis
Multiple bullish analyses highlight Agilent's potential, with strong performance indicators like a forward P/E of 20.37 and a share price of $120.96 as of April 20th.
Global Market Presence
Agilent operates worldwide, offering instruments, software, and services, supported by trade shows, conferences, and webinars to engage customers and drive adoption.
Life Sciences and Diagnostics Focus
The company's strong position in life sciences, diagnostics, and applied chemical markets provides stable revenue streams and growth opportunities.
High-Speed Technology Innovation
Agilent's advanced solutions, such as 200+ Gbaud multi-level modulated signals, demonstrate its capability to meet high-performance demands in digital and optical standards.
Comprehensive Product Portfolio
Agilent offers a wide range of products, including consumables, software, and services, making it a one-stop solution for laboratory needs.
A real bull case compounds — each driver matters most when it strengthens margins, supports capital returns, and keeps the company above the market's minimum growth bar simultaneously.
A Stock Price Performance
52-week range context and price returns across multiple time horizons. Dividend contribution is shown separately in the Capital Return section.
Current Price
$127.06
52W Range Position
36%
52-Week Range
Current price plotted between the 52-week low and high.
52-Week Low
$108.35
+17.3% from the low
52-Week High
$160.27
-20.7% from the high
1 Month
+13.34%
3 Month
+13.96%
YTD
-7.9%
1 Year
+10.0%
3Y CAGR
+2.5%
5Y CAGR
-2.6%
10Y CAGR
+10.7%
Range context matters because valuation compression and earnings misses rarely hit from the same starting point. A stock already far below its high can still fall, but it is no longer carrying the same embedded optimism as one pressing a fresh peak.
A vs Peers
Valuation, growth, and margin comparison against the closest publicly traded peers for this company.
Peer Set
Accurate peer set
Forward PE
21.0x
vs 24.5x median
-14% below peer median
Revenue Growth
+2.7%
vs +6.1% median
-55% below peer median
Net Margin
19.6%
vs 14.9% median
+31% above peer median
| Company | Mkt Cap | Fwd PE | Rev Grw | Margin | Rating | Upside |
|---|---|---|---|---|---|---|
A A Agilent Technologies, Inc. | $35.9B | 21.0x | +2.7% | 19.6% | Buy | +21.8% |
WAT WAT Waters Corporation | $23.2B | 24.5x | +18.4% | 11.9% | Hold | +11.2% |
TMO TMO Thermo Fisher Scientific Inc. | $172.7B | 18.7x | +6.1% | 15.2% | Buy | +29.1% |
DHR DHR Danaher Corporation | $125.4B | 21.0x | +3.5% | 14.9% | Buy | +30.3% |
BRK BRKR Bruker Corporation | $8.7B | 27.0x | +8.8% | -0.3% | Buy | -16.7% |
MTD MTD Mettler-Toledo International Inc. | $23.1B | 24.5x | +3.9% | 21.4% | Hold | +21.6% |
This peer comparison reflects companies with similar business models, product lines, or market positioning, supplemented by industry grouping when direct matches are limited.
A Dividend and Capital Return
A returns capital mainly through $425M/year in buybacks (1.2% buyback yield), with a modest 0.78% dividend — combining for 2.0% total shareholder yield.
Dividend SustainableFCF Well Covered
Total Shareholder Yield
2.0%
Dividend + buyback return per year
Buyback Yield
1.2%
Dividend Yield
0.78%
Payout Ratio
21.6%
How A Splits Its Return
Div 0.78%
Buyback 1.2%
Dividend 0.78%Buybacks 1.2%
Dividend Profile
Yield, cadence, and growth quality
Dividend / Share
Trailing annualized cash dividend
$0.99
Growth Streak
Consecutive years of dividend increases
0Y
3Y Div CAGR
-11.3%
5Y Div CAGR
6.6%
Ex-Dividend Date
—
Payment Cadence
Quarterly
5 payments over the last 12 months
Buyback Engine
How much per-share support comes from repurchases
Repurchases (TTM)
Cash used for buybacks in the latest trailing period
$425M
Estimated Shares Retired
3M
Approx. Share Reduction
1.2%
Shares Outstanding
Current diluted share count from the screening snapshot
282M
At 1.2%/year, buybacks mechanically lift EPS even with flat earnings — each remaining share represents a slightly larger piece of the company.
| Year | Div / Share | YoY Grw | BB Yield | Total Yield |
|---|---|---|---|---|
| 2026 | $0.77 | — | — | — |
| 2025 | $0.74 | -22.2% | 1.0% | 1.7% |
| 2024 | $0.96 | +4.9% | 3.0% | 3.8% |
| 2023 | $0.91 | -14.5% | 1.9% | 2.7% |
| 2022 | $1.06 | +37.2% | 2.7% | 3.3% |
FAQ
7 questionsA Investor Questions
Common questions answered from live analyst data and company financials.
01Is Agilent Technologies, Inc. (A) stock a buy or sell in 2026?
Agilent Technologies, Inc. (A) is rated Buy by Wall Street analysts as of 2026. Of 41 analysts covering the stock, 32 rate it Buy or Strong Buy, 8 rate it Hold, and 1 rate it Sell or Strong Sell. The consensus 12-month price target is $155, implying +21.8% from the current price of $127. The bear case scenario is $104 and the bull case is $218.
02What is the A stock price target for 2026?
The Wall Street consensus price target for A is $155 based on 41 analyst estimates. The high-end target is $165 (+29.9% from today), and the low-end target is $140 (+10.2%). The base case model target is $166.
03Is Agilent Technologies, Inc. (A) stock overvalued in 2026?
A trades at 21.0x times forward earnings. The stock's valuation is broadly in line with the broader market. Based on current multiples versus the peer group, the relative model signals slightly cheap versus peers. Whether the stock is over or undervalued ultimately depends on whether consensus earnings estimates are achievable.
04What are the main risks for Agilent Technologies, Inc. (A) stock in 2026?
The primary risks for A in 2026 are: (1) Revenue guidance risks — While Agilent raised full-year 2026 revenue guidance, market concerns persist about achieving these targets amid external pressures. (2) Global tariffs impact — Persisting pressures from global tariffs are affecting Agilent's performance despite stable fundamentals. (3) Supply chain issues — Supply chain disruptions are contributing to downward pressure on Agilent's stock despite positive long-term outlook. Each factor has the potential to pressure earnings or compress the stock's valuation multiple.
05What is Agilent Technologies, Inc.'s revenue and earnings forecast?
Analyst consensus estimates A will report consensus revenue of $7.4B (+2.7% year-over-year) and EPS of $5.45 (+9.5% year-over-year) for the upcoming fiscal year. The following year, analysts project $7.8B in revenue.
06When does Agilent Technologies, Inc. (A) report its next earnings?
A confirmed upcoming earnings date for A is not yet available. Check the Earnings section above for the most recent quarterly report dates and forward estimates.
07How much free cash flow does Agilent Technologies, Inc. generate?
Agilent Technologies, Inc. (A) generated $1.3B in free cash flow over the trailing twelve months — a free cash flow margin of 17.4%. A returns capital to shareholders through dividends (0.8% yield) and share repurchases ($425M TTM).